DE202023001978U1 - Formulation comprising Coenzyme Q10 and creatine - Google Patents
Formulation comprising Coenzyme Q10 and creatine Download PDFInfo
- Publication number
- DE202023001978U1 DE202023001978U1 DE202023001978.8U DE202023001978U DE202023001978U1 DE 202023001978 U1 DE202023001978 U1 DE 202023001978U1 DE 202023001978 U DE202023001978 U DE 202023001978U DE 202023001978 U1 DE202023001978 U1 DE 202023001978U1
- Authority
- DE
- Germany
- Prior art keywords
- formulation
- vitamin
- formulation according
- creatine
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 238000009472 formulation Methods 0.000 title claims abstract description 53
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title claims abstract description 20
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 12
- 229960003624 creatine Drugs 0.000 title claims abstract description 10
- 239000006046 creatine Substances 0.000 title claims abstract description 10
- 229940110767 coenzyme Q10 Drugs 0.000 title claims abstract description 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 9
- 239000000839 emulsion Substances 0.000 claims abstract description 10
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 5
- -1 amino acid compound Chemical class 0.000 claims description 5
- UFUWQSYRGLMLKP-UHFFFAOYSA-N creatine ethyl ester Chemical compound CCOC(=O)CN(C)C(N)=N UFUWQSYRGLMLKP-UHFFFAOYSA-N 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 229940049920 malate Drugs 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- 229930003451 Vitamin B1 Natural products 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 229960003646 lysine Drugs 0.000 claims description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 235000010374 vitamin B1 Nutrition 0.000 claims description 2
- 239000011691 vitamin B1 Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Abstract
Formulierung umfassend Coenzym Q10 und eine Kreatin-Quelle, dadurch gekennzeichnet, dass die Formulierung eine stabile, liposomale, unter Zellaufschluss-Bedingungen erzeugte Emulsion ist.Formulation comprising coenzyme Q10 and a creatine source, characterized in that the formulation is a stable, liposomal emulsion produced under cell disruption conditions.
Description
WISSENSCHAFTLICHER BEREICHSCIENTIFIC AREA
Die vorliegende Erfindung kann dem wissenschatlichen Bereich der Formulierungen wie z. B. im Bereich der Nahrungsergänzungsmittel zugeordnet werden. Solche Formulierungen dienen häufig zur Vervollständigung der für einen ausgewogenen Stoffwechsel notwendigen Versorgung und enthalten in der vorgesehenen Dosierung die im Durchschnitt notwendige Tages- oder Wochen-Dosis an Verbindungen und Mineralien, um bei unausgewogener oder saisonal bedingt einseitiger Ernährung die hilfreichen Nährstoffe ergänzend bereitzustellen. Weiterhin dienen Formulierungen solcher Art auch zur begleitenden Ergänzung von Diät-, Therapie- oder auch Heil-Konzepten des medizinischen Bereichs. Die allgemeine Verwendung von liposomalen Formulierungen ist bekannt. Hierzu sei zum Beispiel auf die
ALLGEMEINER HINTERGRUNDGENERAL BACKGROUND
Die vorliegende Erfindung betrifft Formulierungen gemäß dem Oberbegriff der unabhängigen Schutzansprüche. Der Erfinder baut hierbei auf Grundlagen auf, wie sie in seinen vorherigen Anmeldungen wie z. B.
BESCHREIBUNG DES STANDES DER TECHNIKDESCRIPTION OF THE PRIOR ART
Etablierte Formulierungen welche zum menschlichen Energiehaushalt beitragen können sind zum Beispiel in den Dokumenten
Aus der
Nachteilig ist, dass eine Injektion eine sehr geringe Kunden-Akzeptanz hat. Alternative Methoden mit Mikropulver-Druckluft-Injektoren o. Ä. konnten sich ebenso nicht durchsetzen.The disadvantage is that an injection has very low customer acceptance. Alternative methods with micropowder compressed air injectors or similar. could not prevail either.
Für die bekannten, liposomalen Formulierungen wurden Effekte, wie sie bei einer Injektion messbar sind, bisher nicht berichtet.Effects such as those that can be measured during an injection have not yet been reported for the known liposomal formulations.
Der Erfinder führt diesen Nachteil darauf zurück, dass die etablierten, liposomalen Formulierungen durch verschieden zusammengesetzte Micellen, eine breitere Spreitung der mittleren Micellengröße, Instabilität der Emulsion und auch durch Zusätze, welche in parallelen und ergänzenden Verwertungskreisläufen aktiv sind, keine optimale Bioverfügbarkeit im Sinne einer Kinetik, die einer Injektion zumindest nahe kommt, erreichen.The inventor attributes this disadvantage to the fact that the established liposomal formulations do not have optimal bioavailability in the sense of kinetics due to differently composed micelles, a wider spread of the average micelle size, instability of the emulsion and also additives that are active in parallel and complementary utilization cycles , which at least comes close to an injection.
Aufgabe der vorliegenden Erfindung war es daher, die Nachteile des Standes der Technik zu überwinden und eine Formulierung des Typs ‚Q10 + Kreatin‘ bereitzustellen, welche bei oraler Aufnahme trotz notwendiger Begleitstoffe die Kernkomponenten hochgradig bioverfügbar für eine Unterstützung des muskulären Energiehaushalts im Minutenbereich bereitzustellen vermag.The object of the present invention was therefore to overcome the disadvantages of the prior art and to provide a formulation of the 'Q10 + creatine' type, which, when taken orally despite the necessary accompanying substances, is able to provide the core components in a highly bioavailable manner to support the muscular energy balance in a matter of minutes.
Die Lösung dieser Aufgabe erfolgt gemäß der Merkmale der unabhängigen Schutzansprüche. Vorteilhafte Ausführungsformen ergeben sich aus den abhängigen Ansprüchen sowie der nachfolgenden Beschreibung.This task is solved in accordance with the characteristics of the independent protection claims. Advantageous embodiments result from the dependent claims and the following description.
ZUSAMMENFASSUNG DER ERFINDUNGSUMMARY OF THE INVENTION
Erfindungsgemäß umfasst eine Formulierung Coenzym Q10 und eine Kreatin-Quelle, wobei die Formulierung eine stabile, liposomale, unter Zellaufschluss-Bedingungen erzeugte Emulsion ist.According to the invention, a formulation comprises coenzyme Q10 and a creatine source, the formulation being a stable, liposomal emulsion produced under cell disruption conditions.
BESCHREIBUNG DER ERFINDUNG UND VORTEILHAFTER MERKMALEDESCRIPTION OF THE INVENTION AND ADVANTAGEOUS FEATURES
Erfindungsgemäß umfasst eine Formulierung Coenzym Q10 und eine Kreatin-Quelle, wobei die Formulierung eine stabile, liposomale, unter Zellaufschluss-Bedingungen erzeugte Emulsion ist.According to the invention, a formulation comprises coenzyme Q10 and a creatine source, the formulation being a stable, liposomal emulsion produced under cell disruption conditions.
Liposomale Emulsionen weisen Mikrotröpfchen auf. Vorliegend wird die Emulsion unter Zellaufschluss-Bedingungen gewonnen und/oder erzeugt. Durch Verwendung physiologisch kompatibler, möglichst gleichmäßiger und homogener Liposom-Bausteine können durch hohe Druck- sowie Scher-Kräfte, die bei Zellaufschluss-Verfahren angewendet werden, einheitlichere Tröpfchen-Fraktionen erhalten werden, welche das Umschlossene stabilisieren und auch schneller durch Membranen transportieren können. Die Bioverfügbarkeit ist dadurch besser und gleichmäßiger eingestellt, die Haltbarkeit gesteigert und die Lagerfähigkeit gut bis sehr gut.Liposomal emulsions have microdroplets. In the present case, the emulsion is obtained and/or produced under cell disruption conditions. By using physiologically compatible liposome building blocks that are as uniform and homogeneous as possible, more uniform droplet fractions can be obtained through the high pressure and shear forces used in cell disruption processes, which stabilize the enclosed material and can also transport it more quickly through membranes. The bioavailability is therefore better and more uniform, the shelf life is increased and the storage life is good to very good.
Besonders vorteilhaft kann eine gleichmäßiger eingestellte, liposomale Formulierung auch in ein homogeneres Trockenprodukt überführt werden; der Erfinder führt Letzteres auch auf die Verwendung von zumindest teilweise amphiphilen Fett-Bausteinen zurück. Durch ausschließlich amphiphile Fettbausteine bricht die Emulsion sogar dann nicht, wenn sie in feinste Tröpfchen verstäubt und gleichzeitig entwässert wird.A more uniform, liposomal formulation can also be particularly advantageous more homogeneous dry product can be transferred; the inventor also attributes the latter to the use of at least partially amphiphilic fat building blocks. Thanks to exclusively amphiphilic fat building blocks, the emulsion does not break even when it is dusted into the finest droplets and dewatered at the same time.
Bevorzugt umfasst die Formulierung mindestens ein Lecithin, besonders bevorzugt ein Lecithin das zu mindestens 20Gewichts% aus Phosphatidylcholin besteht.The formulation preferably comprises at least one lecithin, particularly preferably a lecithin which consists of at least 20% by weight of phosphatidylcholine.
Bevorzugt umfasst die Formulierung mindestens eine weitere Aminosäure-Verbindung, besonders bevorzugt ausgewählt aus der Gruppe von Verbindungen umfassend Lysin, Karnitin, Kreatin, Kreatin-Ethylester-Malat, Cystin, Cystein.The formulation preferably comprises at least one further amino acid compound, particularly preferably selected from the group of compounds comprising lysine, carnitine, creatine, creatine ethyl ester malate, cystine, cysteine.
Bevorzugt umfasst die Formulierung weiterhin mindestens einen Zucker, wobei der mindestens eine Zucker ausschließlich im menschlichen Metabolismus Insulin-unabhängig abbaubare Zucker umfasst.The formulation preferably further comprises at least one sugar, wherein the at least one sugar exclusively comprises sugars that are degradable independently of insulin in human metabolism.
Bevorzugt umfasst die Formulierung mindestens ein weiteres Vitamin, das mindestens eine Vitamin ausgewählt aus der Gruppe bestehend aus Thiamin, Vitamin E, Vitamin C, Vitamin B, Vitamin Bl, Vitamin B12.The formulation preferably comprises at least one further vitamin, which is at least one vitamin selected from the group consisting of thiamine, vitamin E, vitamin C, vitamin B, vitamin B1, vitamin B12.
Bevorzugt umfasst die Formulierung ergänzend zu einem enthaltenen Vitamin mindestens eine weitere Vitamin-Vorläuferverbindung.The formulation preferably comprises at least one further vitamin precursor compound in addition to a vitamin it contains.
Bevorzugt umfasst die Formulierung mindestens ein ohne Gallensäure verstoffwechselbares Fett, das mindestens eine Fett ausgewählt aus der Gruppe bestehend aus mittelkettige Triglyceride, mittelkettige Fettsäuren, mittelkettige Fettsäuresalze.The formulation preferably comprises at least one fat that can be metabolized without bile acid, which is at least one fat selected from the group consisting of medium-chain triglycerides, medium-chain fatty acids, medium-chain fatty acid salts.
Weitere Vorteile ergeben sich aus den Ausführungsbeispielen. Es versteht sich, dass die vorbeschriebenen Merkmale und Vorteile und nachfolgenden Ausführungsbeispiele nicht beschränkend aufzufassen sind. Zusätzliche Maßnahmen, vorteilhafte Merkmale und zusätzliche Merkmalskombinationen, wie sie in der Beschreibung, im wissenschaftlichen Bereich und in den angeführten und den darin zitierten Dokumenten, erläutert sind, können im Rahmen der unabhängigen Ansprüche im beanspruchten Gegenstand sowohl einzeln als auch abweichend kombiniert verwirklicht werden, ohne dass der Bereich der Erfindung verlassen würde.Further advantages result from the exemplary embodiments. It is understood that the features and advantages described above and the following exemplary embodiments are not to be construed as limiting. Additional measures, advantageous features and additional combinations of features, as explained in the description, in the scientific field and in the documents cited and the documents cited therein, can be implemented within the scope of the independent claims in the claimed subject matter both individually and in different combinations, without that would leave the scope of the invention.
DETAILLIERTE ERLÄUTERUNG DER ERFINDUNG AN HAND VONDETAILED EXPLANATION OF THE INVENTION BY
AUSFÜHRUNGBEISPIELENEXEMPLARY EMBODIMENTS
In vorteilhafter Ausführungsform besteht die Formulierung aus Wasser, Xylit, L-Carnitin, Kreatin-Ethyl-Ester-Malat, mittelkettige Triglyceride, Coenzym Q10 und Lecithin mit mindestens 94% Phosphatidylcholin-Gehalt besteht, wobei die Formulierung erhalten wurde durch Ansetzen der vorbeschriebenen Mischung und unmittelbar nachfolgender Ausbildung der liposomalen Schutzhüllen durch Überdruck-Homogenisierung unter Zellaufschluss-Bedingungen. Hierzu im Einzelnen: Rund 400g Wasser werden mit 100g Kreatin Ethylester Malat, 30g Carnitin und 355g Xylit versetzt und verrührt. Anschließend werden 20g Lecithin zugesetzt und die Mischung homogenisiert. Parallel werden 15g Q10 in 50g mittelkettiger Triglyceride bei 50°C gelöst. Die so erzeugte Lösung wird in die homogenisierte Mischung binnen weniger Minuten hineingegossen und dabei dispergiert. Die Dispersion aus Mischung und Lösung wird abschließend unter Zellaufschluss-Bedingungen mit einem Energie-Eintrag im Bereich von 0,1kJ pro Milliliter homogenisiert.In an advantageous embodiment, the formulation consists of water, xylitol, L-carnitine, creatine ethyl ester malate, medium-chain triglycerides, coenzyme Q10 and lecithin with at least 94% phosphatidylcholine content, the formulation being obtained by preparing the mixture described above and immediately following formation of the liposomal protective shells by overpressure homogenization under cell disruption conditions. In detail: Around 400g of water are mixed with 100g creatine ethyl ester malate, 30g carnitine and 355g xylitol and mixed. Then 20g of lecithin are added and the mixture is homogenized. At the same time, 15g of Q10 are dissolved in 50g of medium-chain triglycerides at 50°C. The solution created in this way is poured into the homogenized mixture within a few minutes and dispersed in the process. The dispersion of mixture and solution is finally homogenized under cell disruption conditions with an energy input in the range of 0.1kJ per milliliter.
Die so hergestellte, liposomale Formulierung ist von intensiver, orangegelber Farbe und zeigt auch unter UV-Licht keine Strukturen, Schlieren oder Inhomogenitäten. Eine Lagerfähigkeit von mehreren Monaten konnte sogar in einfachen, kostengünstigen Glasgefäßen ohne UV- oder LichtSchutz nachgewiesen werden.The liposomal formulation produced in this way has an intense, orange-yellow color and does not show any structures, streaks or inhomogeneities even under UV light. A shelf life of several months has even been proven in simple, inexpensive glass containers without UV or light protection.
In einer ersten Studie ergaben sich für Kraftsportler im Vergleich zu einer Placebo-Testgruppe kurzfristig binnen 10 bis 20 Minuten nach Einnahme feststellbare Steigerungen der Schnellkraft im Sinne einer kontinuierlich abrufbaren, gesteigerten Leistung um 4% bis 11%. Überraschend konnte aus der wie vorbeschrieben hergestellten Formulierung durch Sprühtrocknung ein sehr gleichmäßiges, feines Granulat erhalten werden, welches von den Probanden sogar als Granulat direkt eingenommen als organoleptisch angenehm beschrieben wurde und vergleichbare Leistungssteigerungen von 5% bis 10,5% ermöglichte.In a first study, strength athletes showed noticeable increases in speed strength in the sense of a continuously accessible, increased performance of 4% to 11% within 10 to 20 minutes after taking the drug compared to a placebo test group. Surprisingly, very uniform, fine granules could be obtained from the formulation prepared as described above by spray drying, which the test subjects even described as organoleptically pleasant when taken directly as granules and enabled comparable increases in performance of 5% to 10.5%.
INDUSTRIELLE ANWENDBARKEITINDUSTRIAL APPLICABILITY
Nachteil etablierter, oral einzunehmender Formulierungen des Typs ‚Kreatin + Q10‘ ist, dass diese eine Unterstützung des Energiehaushalts binnen Minuten, wie er bei Injektionen erzielt werden kann, nicht bereitstellen.The disadvantage of established, oral formulations of the type 'Creatine + Q10' is that they do not provide support for energy balance within minutes, as can be achieved with injections.
Aufgabe ist, diesen Nachteil zu überwinden.The task is to overcome this disadvantage.
Die Lösung erfolgt mit einer Formulierung umfassend Coenzym Q10 und eine Kreatin-Quelle, wobei die Formulierung eine stabile, liposomale, unter Zellaufschluss-Bedingungen erzeugte Emulsion ist. Liposomale Emulsionen umfassen Mikrotröpfchen. Unter Zellaufschluss-Bedingungen erzeugt weist die vorliegende Formulierung eine gleichmäßigere Größenverteilung und hohe Haltbarkeit/Stabilität auf. Kombination mit weiteren Stoffen, welche unabhängig von vorgeschalteten Verwertungs-Mechanismen möglichst direkt mit in den Energiehaushalt einspeisen, stellt eine Bioverfügbarkeit bereit, welche ähnlich einer Injektion binnen weniger Minuten eine Leistungssteigerung bewirken konnte. Durch einfache Sprühtrocknung konnte aus der Formulierung ein überraschend feines und gleichmäßiges Granulat gewonnen werden, welches sogar bei direkter, oraler Aufnahme von den Probanden als organoleptisch angenehm und in der Leistungssteigerung gleichwirkend beschrieben wurde.The solution is carried out with a formulation comprising coenzyme Q10 and a creatine source, the formulation being a stable, liposomal emulsion produced under cell disruption conditions. Liposomal emulsions include microdroplets. Produced under cell disruption conditions, the present formulation has a more uniform size distribution and high durability/stability. Combination with other substances, which feed into the energy balance as directly as possible, independently of upstream utilization mechanisms, provides a bioavailability that, similar to an injection, can lead to an increase in performance within a few minutes. Through simple spray drying, a surprisingly fine and uniform granulate was obtained from the formulation, which was described by the test subjects as organoleptically pleasant and had the same effect on increasing performance even when taken directly orally.
ZITATE ENTHALTEN IN DER BESCHREIBUNGQUOTES INCLUDED IN THE DESCRIPTION
Diese Liste der vom Anmelder aufgeführten Dokumente wurde automatisiert erzeugt und ist ausschließlich zur besseren Information des Lesers aufgenommen. Die Liste ist nicht Bestandteil der deutschen Patent- bzw. Gebrauchsmusteranmeldung. Das DPMA übernimmt keinerlei Haftung für etwaige Fehler oder Auslassungen.This list of documents listed by the applicant was generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.
Zitierte PatentliteraturCited patent literature
- WO 002007002897 A [0001]WO 002007002897 A [0001]
- EP 0736299 A1 [0001]EP 0736299 A1 [0001]
- EP 2537515 A1 [0002]EP 2537515 A1 [0002]
- DE 202013002498 U1 [0002]DE 202013002498 U1 [0002]
- DE 202018005540 U1 [0002]DE 202018005540 U1 [0002]
- DE 202023001867 U1 [0002]DE 202023001867 U1 [0002]
- US 6080788 A [0003]US 6080788 A [0003]
- US 6479540 B1 [0003]US 6479540 B1 [0003]
- US 20080103202 A1 [0003]US 20080103202 A1 [0003]
- GB 2178661 A1 [0004]GB 2178661 A1 [0004]
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE202023001978.8U DE202023001978U1 (en) | 2023-09-20 | 2023-09-20 | Formulation comprising Coenzyme Q10 and creatine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE202023001978.8U DE202023001978U1 (en) | 2023-09-20 | 2023-09-20 | Formulation comprising Coenzyme Q10 and creatine |
Publications (1)
Publication Number | Publication Date |
---|---|
DE202023001978U1 true DE202023001978U1 (en) | 2023-09-29 |
Family
ID=88414506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE202023001978.8U Active DE202023001978U1 (en) | 2023-09-20 | 2023-09-20 | Formulation comprising Coenzyme Q10 and creatine |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE202023001978U1 (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2178661A (en) | 1985-08-06 | 1987-02-18 | Seuref Ag | Pharmaceutical compositions containing ubiquinone coenzymes |
EP0736299A1 (en) | 1995-04-03 | 1996-10-09 | Cerbios-Pharma S.A. | Process for preparing a liposomal, water-dispersable, solid, dry, therapeutic formulation for oral administration |
US6080788A (en) | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
US6479540B1 (en) | 1999-09-27 | 2002-11-12 | Sonus Pharmaceuticals, Inc. | Compositions of tocol-soluble therapeutics |
WO2007002897A2 (en) | 2005-06-28 | 2007-01-04 | Kgk Synergize Inc. | Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for treatment of cardiovascular disease |
US20080103202A1 (en) | 2004-11-08 | 2008-05-01 | Chris Ferguson | Method of preparing creatine ester salts and uses thereof. |
EP2537515A1 (en) | 2011-06-22 | 2012-12-26 | Wolfgang Langhoff | Dietetic product for treating mitochondrial dysfunctions |
DE202013002498U1 (en) | 2013-03-15 | 2013-03-22 | Wolfgang Langhoff | Feed additive for pets and pets |
DE202018005540U1 (en) | 2018-12-02 | 2019-03-01 | Gertrud Langhoff | Improved, emulsified carbohydrate concentrate |
DE202023001867U1 (en) | 2023-09-03 | 2023-10-17 | Penta Phi Eg | Formulation comprising at least one type of cress |
-
2023
- 2023-09-20 DE DE202023001978.8U patent/DE202023001978U1/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2178661A (en) | 1985-08-06 | 1987-02-18 | Seuref Ag | Pharmaceutical compositions containing ubiquinone coenzymes |
EP0736299A1 (en) | 1995-04-03 | 1996-10-09 | Cerbios-Pharma S.A. | Process for preparing a liposomal, water-dispersable, solid, dry, therapeutic formulation for oral administration |
US6080788A (en) | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
US6479540B1 (en) | 1999-09-27 | 2002-11-12 | Sonus Pharmaceuticals, Inc. | Compositions of tocol-soluble therapeutics |
US20080103202A1 (en) | 2004-11-08 | 2008-05-01 | Chris Ferguson | Method of preparing creatine ester salts and uses thereof. |
WO2007002897A2 (en) | 2005-06-28 | 2007-01-04 | Kgk Synergize Inc. | Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for treatment of cardiovascular disease |
EP2537515A1 (en) | 2011-06-22 | 2012-12-26 | Wolfgang Langhoff | Dietetic product for treating mitochondrial dysfunctions |
DE202013002498U1 (en) | 2013-03-15 | 2013-03-22 | Wolfgang Langhoff | Feed additive for pets and pets |
DE202018005540U1 (en) | 2018-12-02 | 2019-03-01 | Gertrud Langhoff | Improved, emulsified carbohydrate concentrate |
DE202023001867U1 (en) | 2023-09-03 | 2023-10-17 | Penta Phi Eg | Formulation comprising at least one type of cress |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH653891A5 (en) | MEANS FOR ORAL ADMINISTRATION TO A HUMAN AND / OR MAMMAL. | |
EP0711557A1 (en) | Base for formulating pharmaceutical agents | |
DE202013104575U1 (en) | Mixture of microencapsulated amino acids | |
EP0125634B1 (en) | Use of a secretolytically active substance for the manufacture of a remedy against snoring and for combating snore phenomenon | |
EP0250648A2 (en) | Pharmaceutical preparation for the sustained release of ibuprofen | |
EP1569724A1 (en) | Formulations containing melatonin, ginkgo biloba, and biotin | |
WO1999025332A1 (en) | Composition with azelaic acid | |
DE2425264A1 (en) | COMPOSITIONS FOR THE TREATMENT OF DIGESTIVE UTILITIES | |
CH646056A5 (en) | LIPID LOWERING AGENT. | |
DE3115080A1 (en) | MEDICINAL PRODUCTS FOR ORAL ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF | |
EP1660097B1 (en) | Physiologically active composition based on phosphatidylserine | |
DE202023001867U1 (en) | Formulation comprising at least one type of cress | |
EP0211204B1 (en) | Process for the preparation of a stable aqueous fat emulsion and its use in parenterally administered complete nutrient solutions | |
EP0273407B1 (en) | Medicine for improving the specific properties of blood | |
DE202023001978U1 (en) | Formulation comprising Coenzyme Q10 and creatine | |
EP0035597A2 (en) | Pharmaceutical preparations | |
DE60124516T3 (en) | COMBINATION OF THE LEZITHINE WITH ASCORBIC ACID | |
DE3035494A1 (en) | CARNITIN CONTAINING MEDICINE FOR TREATING HYPERLIPIDAEMIA AND HYPERLIPOPROTEINAEMIA, AND USE OF CARNITIN FOR PRODUCING SUCH A MEDICINAL PRODUCT | |
DE1692598A1 (en) | Process for the production of fortified sugar | |
DE69533742T2 (en) | Use of proline and / or derivatives as anti-hepatitis agents | |
DE3609005A1 (en) | PHARMACEUTICAL COMPOSITIONS WITH METABOLIC ACTIVITY | |
DE60206545T2 (en) | Composition for drinking / eating containing AGARICUS BLAZEI MURRILL | |
DE60123132T2 (en) | LIPOSOME FORMULATION WITH CLOBETASOL PROPIONATE | |
WO1992013524A1 (en) | Pharmaceutical for treating viral diseases | |
DE2117762A1 (en) | Treatment of alopecia and pharmaceutical preparation for carrying out the treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R207 | Utility model specification |